ALK-Abello A/S - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for ALK-Abello A/S Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

ALK-Abello A/S. The principal activity of the Group is developing products for diagnosis, prevention and treatment of allergies. The Group operates through one business area namely: Allergy sector. The Allergy sector operates within allergy vaccination - injection-based and drop-based vaccines, the only treatment able to cure allergy rather than just alleviate symptoms. In addition to the existing business, the Group has developed a pipeline of projects which have the potential to bring crucial, innovative change to the treatment and cure of allergy. The Group operates subsidiaries in France, Netherlands, Italy, Sweden, Germany, UK and USA, and has sales offices in China, Finland, Norway and Denmark. In fiscal 2006 the Group introduced the new vaccine GRAZAX on the market.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report